Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Views & Analysis Infographic: Solving the challenges of immuno-oncology trial... The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Eye on ESMO: Day Three - Merck & Co. wins big lung cancer ba... Merck unveils impressive data on Keytruda, trumping BMS' Opdivo
ESMO2016 Cancer market commentary: 3 highlights from ESMO (Part 1) Commentary on key cancer data from ESMO by Stephanie Hawthorne
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
